Navigation Links
Mapping of protein inhibitors facilitates development of tailor-made anticancer agents
Date:2/21/2012

A team of researchers at Karolinska Institutet in Sweden has generated a map over the effects of small drug-like molecules on PARP1 and other similar proteins in the body. This map may explain the mechanism behind putative side effects of the so-called PARP inhibitors, and can play an important role in the development of novel tailor-made cancer drugs. The study is presented in the journal Nature Biotechnology, and will hopefully contribute to new cancer therapies with fewer detrimental side effects.

PARP1 is a protein with enzymatic activity that governs repair of DNA damage in our cells. In the past decade, PARP1 has been in the focus for a large number of industrial drug development projects, primarily targeting breast and ovarian cancers. More than 50 clinical studies have been initiated around the world.

In the current study, the researchers at Karolinska Institutet have tested the effects of small drug-like molecules inhibitors on PARP1 and other enzymes of the same class. The effects of 180 substances on 13 different human PARP enzymes were studied. Many of the drugs that are currently being tested in clinical studies were part of the survey.

"Our results give us a map over the effects of a number of known but also less well characterized drug-like compounds on different PARP enzymes", says Herwig Schler, who headed the study at the Department of Medical Biochemistry and Biophysics. "Studying the cross-reactivity of less well characterized compounds on different PARP enzymes is especially interesting, since it can give clues to the interpretation of clinical side effects."

The chemical interaction map was complemented with high-resolution structural information, showing at atomic detail how inhibitors bind to these PARP enzymes. Together, the results give unique insights into specificity and cross-reactivity of PARP inhibitors. This in turn will be an important hallmark toward development of selective PARP inhibitors tailor-made substances that can inhibit one PARP enzyme while leaving the others unaffected.

This project builds upon a long-standing industry collaboration that Karolinska Institutet has participated in within the Structural Genomics Consortium 2005-2010. The study published in Nature Biotechnology is the result of collaboration between the research group at KI, the University of Perugia (Italy), Actar AB, and GE Healthcare.


'/>"/>

Contact: Katarina Sternudd
katarina.sternudd@ki.se
46-852-483-895
Karolinska Institutet
Source:Eurekalert

Related medicine news :

1. CSHL team introduces automated imaging to greatly speed whole-brain mapping efforts
2. Fast new method for mapping blood vessels may aid cancer research
3. Blood vessel mapping reveals 4 new ZIP codes
4. Gene Mapping Reveals Clues to Bedbugs Pesticide Resistance
5. Roadmap published for dynamic mapping of estrogen signaling in breast cancer
6. Mapping faculty social networks helps female faculty move ahead at NJIT
7. Mapping a brain atlas
8. ELLKAY Introduces Revolutionary Live Insurance Mapping Solution for Diagnostic Laboratories
9. A single protein helps the body keep watch over the Epstein-Barr virus
10. CD97 gene expression and function correlate with WT1 protein expression and glioma invasiveness
11. Protein structures give disease clues
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... , ... June 26, 2016 , ... Brent Kasmer, a legally blind and certified personal ... personalized through a fitness app. The fitness app plans to fix the two major problems ... offer a one size fits all type program , They don’t eliminate all ...
(Date:6/25/2016)... ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library on June ... , brings up a new, often overlooked aspect of head lice: the parasite’s ability to ... is not a common occurrence, but a necessary one in the event that lice have ...
(Date:6/25/2016)... Oklahoma City, Oklahoma (PRWEB) , ... June 25, ... ... to helping both athletes and non-athletes recover from injury. Recently, he has implemented ... for the Oklahoma City area —Johnson is one of the first doctors to ...
(Date:6/24/2016)... ... ... Those who have experienced traumatic events may suffer from a complex set of ... or alcohol abuse, as a coping mechanism. To avoid this pain and suffering, Serenity ... event. , Trauma sufferers tend to feel a range of emotions, from depression, guilt, ...
(Date:6/24/2016)... ... ... Global law firm Greenberg Traurig, P.A. announced that 20 Florida attorneys are recognized ... this recognition are considered among the top 2 percent of lawyers practicing within the ... this year’s Legal Elite Hall of Fame: Miami Shareholders Mark D. Bloom, Burt ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... -- Any dentist who has made an implant supported denture ... of them do not even offer this as a viable ... costs involved. And those who ARE able to offer that ... cost that the majority of today,s patients would not be ... , founder of Dental Evolutions Inc. and inventor of Implanova ...
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that it ... (procalcitonin) assay as a dedicated testing solution for people ... Roche is the first IVD company in the U.S ... assessment and management. PCT is a sepsis-specific ... blood can aid clinicians in assessing the risk of ...
(Date:6/23/2016)... 2016 Research and Markets has announced ... report to their offering. ... a favourable commercial environment for MedImmune to enter. The US ... will serve to drive considerable growth for effective anti-influenza medications. ... cap sales considerably, but development is still in its infancy. ...
Breaking Medicine Technology: